Business
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
Sobi® (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza® (olezarsen) reduced the relative risk of acute pancreatitis events by 85% (P<0.001) and reduced triglycerides by 66% in patients with severe hypertriglyceridemia (sHTG) after six months.[1]
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"STOCKHOLM, May 26, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza® (olezarsen) reduced the relative risk of acute pancreatitis events by 85% (P<0.001) and reduced triglycerides by 66% in patients with severe hypertriglyceridemia (sHTG) after six months.[1]","length":359,"tagName":"p"},{"type":"text","content":"The pooled subgroup analysis, presented as a late breaking abstract at the European Atherosclerosis Society (EAS) 2026 Congress in Athens, Greece, included 455 patients with baseline triglycerides of ≥880 mg/dL (~10 mmol/L), defined by the EAS as severe hypertriglyceridemia. At six months, patients randomised to receive olezarsen 80 mg showed a placebo-adjusted reduction in triglycerides of 66%, and those on olezarsen 50 mg a 59% reduction (each P<0.001). Overall, 85% of olezarsen-treated patients achieved triglycerides of <10 mmol/L.1","length":547,"tagName":"p"},{"type":"text","content":""Acute pancreatitis is a painful and potentially life-threatening condition that often requires urgent hospitalisation. People with triglyceride levels above 10 mmol/L have a four times greater risk of acute pancreatitis compared to those with ideal low levels, and this risk increases progressively as triglyceride levels rise[2]. According to EAS/ESC guidelines, triglyceride levels above 10 mmol/L warrant urgent intervention to prevent acute pancreatitis[3]," said Børge Nordestgaard, Professor and Chief Physician at Copenhagen University Hospital. "This new analysis showed that olezarsen reduced acute pancreatitis risk by 85% in patients with baseline triglyceride levels ≥10 mmol/L, while the vast majority of patients achieved triglyceride levels below 10 mmol/L."","length":794,"tagName":"p"},{"type":"text","content":"Severe hypertriglyceridemia is the third most common cause of acute pancreatitis.[4] The incidence of acute pancreatitis globally has increased at an average annual rate of 3% since the 1960s, contributing to a growing burden on healthcare systems.[5]","length":251,"tagName":"p"},{"type":"text","content":""These results add to the collective body of evidence for olezarsen, showing the reduction of acute pancreatitis risk in severe hypertriglyceridemia. As rates of acute pancreatitis continue ...